venBio Partners
venBio is a life sciences investment firm that partners with industry leaders to build game-changing medicines and technologies.
Business Model:
Revenue: $5.7M
Employees: 2-10
Rankings
Industries / Tags:
Detailed venBio Partners Information
Geographic Data
Address: 1700 Owens St
City: San Francisco
State: CA
Zip: 94158
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$2B
Social
Facebook
Linkedin
Crunchbase
Metrics
9,736,746Website Global Rank
107Website Monthly Traffic
Twitter Followers
Description
venBio invests in promising companies at various stages: from early to late stage, and from academic startups to spinouts. We tend to lead most of our investments, and we enjoy building syndicates and teams. We are mindful of potential acquisition partners from the outset, and we ensure that our companies are best positioned to meet their requirements. This includes IP, CMC, and the details of clinical trials, including indication, trial design, endpoints, powering, and regulatory considerations. Our team’s expertise and involvement helps companies make a bigger impact, and this leads to impactful and lasting relationships with the leaders that we work with.
Contact Phone:
+14158000800
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 10/2019 | INBRACE | Series C | 45M |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 1/2021 | FogPharma | Series C | 107M |
| 9/2019 | Pharvaris | Series B | 66M |
| 8/2021 | Neurogastrx | Series B | 60M |
| 7/2015 | Outlook Therapeutics | Venture Round | 31M |
| 10/2021 | HistoWiz | Series A | 32.3M |
| 2/2015 | Cidara Therapeutics | Series B | 42M |
| 3/2017 | ALX Oncology | Convertible Note | 25M |
| 4/2014 | Heart Metabolics | Series A | 20M |
| 6/2018 | Akero Therapeutics | Series A | 65M |
| 12/2013 | Stem Cell Therapeutics | Post-IPO Equity | 0 |
| 11/2020 | Pharvaris | Series C | 80M |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 2/2014 | Aurinia Pharmaceuticals | Post-IPO Equity | 52M |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 1/2018 | Neurogastrx | Series A | 45M |
| 9/2020 | Attralus | Series A | 25M |
| 2/2016 | Apellis Pharmaceuticals | Series D | 47M |
| 12/2016 | Impel NeuroPharma | Series C | 36M |
| 11/2020 | Elevation Oncology | Series B | 65M |
| 2/2020 | ALX Oncology | Series C | 105M |
| 12/2018 | Akero Therapeutics | Series B | 70M |
| 3/2015 | ALX Oncology | Series A | 36M |
| 6/2020 | Artiva Biotherapeutics | Series A | 0 |
| 10/2013 | Seragon Pharmaceuticals | Series A | 30M |
| 10/2020 | RayzeBio | Series A | 45M |
| 12/2018 | Impel NeuroPharma | Series D | 67.5M |
| 12/2020 | Tallac Therapeutics | Series A | 62M |
| 11/2020 | Stargazer Pharmaceuticals | Series A | 0 |
| 9/2015 | Outlook Therapeutics | Venture Round | - |
| 9/2021 | Attralus | Series B | 116M |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 8/2014 | Bellicum Pharmaceuticals | Series C | 55M |
| 3/2012 | Cytos | Post-IPO Equity | 40M |
| 12/2022 | Entact Bio | Series A | 81M |
| 1/2020 | NorthSea Therapeutics | Series B | 40M |
| 12/2012 | Solstice Biologics | Private Equity Round | 7.5M |
| 8/2015 | Checkmate Pharmaceuticals | Series A | 20M |
| 1/2013 | Labrys Biologics | Series A | 31M |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 6/2020 | Checkmate Pharmaceuticals | Series C | 85M |
| 9/2014 | Adaptimmune | Series A | 0 |
| 10/2017 | Harmony Biosciences | Venture Round | 0 |
| 7/2017 | VYNE Therapeutics | Series C | 50.5M |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 9/2022 | ACELYRIN | Series C | 0 |
| 6/2018 | Metacrine | Series C | 65M |
| 10/2012 | Aragon Pharmaceuticals, Inc. | Series D | 50M |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 12/2018 | Checkmate Pharmaceuticals | Series C | 22M |
| 8/2015 | Metacrine | Series A | 36M |
| 11/2021 | ACELYRIN | Series B | 0 |
| 2/2021 | Artiva Biotherapeutics | Series B | 120M |
| 12/2020 | RayzeBio | Series B | 105M |
| 6/2021 | RayzeBio | Series C | 108M |
| 10/2018 | Turning Point Therapeutics | Equity | 80M |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 11/2022 | FogPharma | Series D | 0 |
| 10/2019 | Aeovian Pharmaceuticals | Series A | 0 |
| 12/2017 | Metacrine | Series B | 22M |
| 6/2020 | NFlection Therapeutics | Series A | 20M |
| 8/2017 | Apellis Pharmaceuticals | Series E | 0 |
| 6/2017 | Checkmate Pharmaceuticals | Series B | 27M |
| 3/2021 | Ventyx Biosciences | Series A | 0 |
| 1/2013 | Solstice Biologics | Series A | 18M |
| 9/2021 | INBRACE | Series D | 0 |
| 5/2015 | Precision BioSciences | Series A | 0 |
| 1/2022 | ImmPACT Bio | Series B | 0 |
| 1/2022 | Ceptur Therapeutics | Series A | 0 |
| 12/2021 | NorthSea Therapeutics | Series C | 0 |
| 11/2021 | Ablaze Pharmaceuticals | Series A | 0 |
| 11/2021 | ACELYRIN | Series B | 0 |
| 10/2021 | HistoWiz | Series A | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 9/2021 | Ventyx Biosciences | Series B | 0 |
| 9/2021 | INBRACE | Series D | 0 |
| 9/2021 | Attralus | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
